ESVC principal strategy is to create and initially operate life sciences companies founded on intellectual property developed at Yale
Business Model:
Revenue: $8.9M
Employees: 2-10
Address: 33 Whitney Avenue
City: New Haven
State: CT
Zip: 06510
Country: US
ESVC principal strategy is to create and initially operate life sciences companies founded on intellectual property developed at Yale University and other research institutions in the region (from New York City through Southern New England). With experienced management and access to local, professionally managed venture capital, Elm Street Ventures can help scientists build significant technology companies from the seed and early stage. Our partners include successful serial entrepreneurs and experienced corporate managers, who may serve as the interim CEOs or operating chairmen of a number of the companies we form. While they expect to be co-founders of companies in some circumstances, ESVC are also interested in hearing from entrepreneurs, scientists, and engineers who have already formed or plan to form new ventures in the life sciences. Attractive markets, solid patent protection and freedom to operate, defensible market position, and a world class management team are elements ultimately critical for success.
Contact Phone:
+12034014201
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2008 | Retail Optimization | Series B | 1.2M |
6/2007 | BioRelix | Series A | 25.8M |
1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
2/2019 | Halda Therapeutics | Series A | 0 |
2/2008 | Affomix Corporation | Series A | 0 |
1/2009 | Iconic Therapeutics | Venture Round | 2.5M |
10/2009 | Kolltan Pharmaceuticals | Series A | 0 |
6/2019 | Artizan Biosciences | Series A | 0 |
3/2021 | Artizan Biosciences | Series A | 0 |
6/2018 | Iconic Therapeutics | Venture Round | 0 |
3/2017 | P2 Science | Series B | 0 |
3/2021 | Cybrexa Therapeutics | Series B | 25M |
1/2009 | ShareGrove | Seed Round | - |
6/2015 | SeeClickFix | Venture Round | 1.6M |
3/2017 | Saphlux | Series A | 5M |
1/2020 | CellFE | Seed | 4.8M |
5/2012 | Accelerated Orthopedic Technologies | Seed Round | 150k |
4/2014 | P2 Science | Series A | 1M |
9/2013 | Arvinas | Series A | 15M |
4/2010 | Metagenomix | Seed Round | 700k |
1/2020 | P2 Science | Series C | 0 |
5/2013 | P2 Science | Seed Round | 650k |
12/2014 | Device42 | Seed Round | 3.5M |
9/2012 | Desmos | Venture Round | - |
3/2021 | Cybrexa Therapeutics | Series B | 0 |
3/2021 | Artizan Biosciences | Series A | 0 |
1/2020 | P2 Science | Series C | 0 |
1/2020 | CellFE | Seed Round | 0 |
1/2020 | EvolveImmune Therapeutics | Venture Round | 0 |
6/2019 | Artizan Biosciences | Series A | 0 |
2/2019 | Halda Therapeutics | Series A | 0 |
6/2018 | Iconic Therapeutics | Venture Round | 0 |
3/2017 | Saphlux | Series A | 0 |
3/2017 | P2 Science | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|